The Experts below are selected from a list of 105 Experts worldwide ranked by ideXlab platform
Emad Al Muti - One of the best experts on this subject based on the ideXlab platform.
-
Effect of punch configuration on drug release from hydrophilic matrix tablets
2007Co-Authors: Emad Al MutiAbstract:Hydrophilic matrix tablets present a convenient method for oral modified drug delivery. The performance of such dosage forms is affected by multiple factors, amongst which the influence of tablet shape and structural properties have been partially investigated in previous literature. This work focused on investigating the influence of changing tablet properties on the in-vitro behaviour of hydrophilic matrix tablets, in particular, the influence of tablet face curvature on the hydration and drug release behaviour of round and elongated Xanthan Gum tablets containing the two model drugs Orphenadrine Citrate and Orphenadrine Hydrochloride. The influences of tablet overall porosity and of the formulation used on tablet behaviour were also investigated, in addition to the investigation of any interactions between the influences of tablet and formulation variables. Initially the properties of the powders incorporated into the various formulations used were characterised. The physical properties of the dry tablets were then investigated in terms of tablet tensile strength and Abstract 2 structural properties. The hydration behaviour of the various tablets was investigated quantitatively using live in-situ swelling studies and qualitatively using rheological and calorimetric methods. Finally the process of drug and polymer dissolution from the tablets was investigated. The results of the work indicated that tablet face curvature had a significant influence on the physical properties of the dry tablets as well as on the hydration and dissolution patterns associated with the hydrated tablets. The influence of tablet overall porosity was profound on the properties of the dry tablets but became rather minor upon tablet hydration. The type of formulation had a major influence on the properties of dry tablets. Moreover, ionic interactions between the two drugs and Xanthan Gum had a significant influence on the properties of hydrated tablets. Thus, tablet face curvature, porosity of the tablets and physicochemical properties of the drugs need to be considered when formulating a hydrophilic matrix tablet.EThOS - Electronic Theses Online ServiceGBUnited Kingdo
-
Effect of Punch Configuration on Drug Release from Hydrophilic Matrix Tablets
2026Co-Authors: Emad Al MutiAbstract:Hydrophilic matrix tablets present a convenient method for oral modified drug delivery. The performance of such dosage forms is affected by multiple factors, amongst which the influence of tablet shape and structural properties have been partially investigated in previous literature. This work focused on investigating the influence of changing tablet properties on the in-vitro behaviour of hydrophilic matrix tablets, in particular, the influence of tablet face curvature on the hydration and drug release behaviour of round and elongated Xanthan Gum tablets containing the two model drugs Orphenadrine Citrate and Orphenadrine Hydrochloride. The influences of tablet overall porosity and of the formulation used on tablet behaviour were also investigated, in addition to the investigation of any interactions between the influences of tablet and formulation variables. Initially the properties of the powders incorporated into the various formulations used were characterised. The physical properties of the dry tablets were then investigated in terms of tablet tensile strength and Abstract 2 structural properties. The hydration behaviour of the various tablets was investigated quantitatively using live in-situ swelling studies and qualitatively using rheological and calorimetric methods. Finally the process of drug and polymer dissolution from the tablets was investigated. The results of the work indicated that tablet face curvature had a significant influence on the physical properties of the dry tablets as well as on the hydration and dissolution patterns associated with the hydrated tablets. The influence of tablet overall porosity was profound on the properties of the dry tablets but became rather minor upon tablet hydration. The type of formulation had a major influence on the properties of dry tablets. Moreover, ionic interactions between the two drugs and Xanthan Gum had a significant influence on the properties of hydrated tablets. Thus, tablet face curvature, porosity of the tablets and physicochemical properties of the drugs need to be considered when formulating a hydrophilic matrix tablet
A B Barroso - One of the best experts on this subject based on the ideXlab platform.
-
efficacy and safety of combined piroxicam dexamethasone Orphenadrine and cyanocobalamin treatment in mandibular molar surgery
Brazilian Journal of Medical and Biological Research, 2006Co-Authors: A B Barroso, Vilma Lima, G C Guzzo, Rosana A Moraes, Marne Carvalho De Vasconcellos, Mirna Marques Bezerra, F A L Viana, R C R Bezerra, G S M Santana, F A FrotabezerraAbstract:Third molar extraction is a common procedure frequently accompanied by moderate or severe pain, and involves sufficient numbers of patients to make studies relatively easy to perform. The aim of the present study was to determine the efficacy and safety of the therapeutic combination of 10 mg piroxicam, 1 mg dexamethasone, 35 mg Orphenadrine Citrate, and 2.5 mg cyanocobalamin (Rheumazin®) when compared with 20 mg piroxicam alone (Feldene®) in mandibular third molar surgery. Eighty patients scheduled for removal of the third molar were included in this randomized and double-blind study. They received (vo) Rheumazin or Feldene 30 min after tooth extraction and once daily for 4 consecutive days. Pain was determined by a visual analogue scale and by the need for escape analgesia (paracetamol). Facial swelling was evaluated with a measuring tape and adverse effects and patient satisfaction were recorded. There was no statistically significant difference in facial swelling between Rheumazin and Feldene (control group). Both drugs were equally effective in the control of pain, with Rheumazin displaying less adverse effects than Feldene. Therefore, Rheumazin appears to provide a better risk/benefit ratio in the mandibular molar surgery. Since the side effects resulting from nonsteroidal anti-inflammatory drug administration are a severe limitation to the routine use of these drugs in clinical practice, our results suggest that Rheumazin can be a good choice for third molar removal treatment.
-
Efficacy and safety of sombined Piroxicam, Dexamethasone, Orphenadrine and Cyanocobalamin in mandibular molar surgery model
Universidade Federal do CearÃ, 2006Co-Authors: A B BarrosoAbstract:A ExtraÃÃo do terceiro molar à um procedimento comum, freqÃentemente associado com dor de intensidade de moderada ou grave, e que afeta um nÃmero significante de pacientes, o que torna os estudos clÃnicos que avaliam a dor associada com a exodontia dos terceiros molares relativamente fÃceis de se executar. O objetivo deste estudo foi determinar a eficÃcia e a seguranÃa da combinaÃÃo terapÃutica de piroxicam, dexametasona, citrato de orfenadrina e cianocobalamina (RheumazinÂ) em comparaÃÃo ao piroxicam isoladamente (FeldeneÂ) em um modelo de cirurgia do terceiro molar inferior. Neste estudo, que foi do tipo randomizado e duplo cego, foram incluÃdos oitenta pacientes selecionados para a exodontia do terceiro molar inferior. Os pacientes receberam Rheumazin ou Feldene 30 min depois da extraÃÃo do terceiro molar inferior e, a partir daÃ, uma vez ao dia durante 4 dias sucessivos. A intensidade da dor foi determinada por meio de uma escala visual analÃgica e pela quantidade de medicaÃÃo de escape utilizada pelos pacientes (paracetamol). O edema facial foi avaliado atravÃs de medidas da face usando uma escala mÃtrica calibrada (mm). Ainda, foram tambÃm avaliados os efeitos adversos e o grau de satisfaÃÃo em relaÃÃo aos tratamentos, ambos relatados pelos pacientes. Embora os resultados tenham mostrado que nÃo houve diferenÃa estatÃstica no edema facial entre os dois grupos, Rheumazin reduziu a dor na 6a e 120a h de tratamento. Rheumazin tambÃm demonstrou um melhor perfil de seguranÃa, prevenindo efeitos adversos tais como nÃusea, indisposiÃÃo e dor epigÃstrica, dentre outros, quando comparado ao FeldeneÂ. Este achado torna o Rheumazin uma boa opÃÃo para o tratamento no pÃs-operatÃrio da remoÃÃo do terceiro molar inferior.Third molar extraction is a common procedure with pain frequently moderate or severe in intensity, and with sufficient numbers of patients to make studies relatively easy to perform. The aim of this study was to determine the efficacy and the safety of the therapeutic combination of piroxicam, dexamethasone, Orphenadrine Citrate and cyanocobalamin (RheumazinÂ) in comparison to piroxicam alone (FeldeneÂ) in a mandibular third molar surgery model. Eighty patients selected for removal of the third molar were included in this study which was randomized and double blind. They received Rheumazin or Feldene po 30 min after tooth extraction and once daily for 4 consecutive days. Pain was determined by a visual analogue scale and by the need for escape analgesia (paracetamol). Facial swelling was evaluated using a tape measuring method. Record of adverse effects and patientâs satisfaction was also considered. Although the results showed that there was no statistically significant difference in facial swelling between the two groups, Rheumazin reduced pain at 6th and 120th h of treatment. Rheumazin also demonstrated a better safety profile preventing adverse effects including nausea, indisposition and epigastric pain, among others, when compared to FeldeneÂ. This fact makes Rheumazin a good choice for post-surgery treatment in third molar remova
S A Shama - One of the best experts on this subject based on the ideXlab platform.
-
spectrophotometric determination of phenylephrine hcl and Orphenadrine Citrate in pure and in dosage forms
Journal of Pharmaceutical and Biomedical Analysis, 2002Co-Authors: S A ShamaAbstract:A simple and rapid spectrophotometric methods have been estimated for the microdetermination of phenylephrine HCl (I) and Orphenadrine Citrate (II). The proposed methods are based on the formation of ion-pair complexes between the examined drugs with alizarine (Aliz), alizarine red S (ARS), alizarine yellow G (AYG) or quinalizarine (Qaliz), which can be measured at the optimum lambda(max). The optimization of the reaction conditions is investigated. Beer's law is obeyed in the concentration ranges 2-36 microgram ml(-1), whereas optimum concentration as adopted from Ringbom plots was 3.5-33 microgram ml(-1). The molar absorptivity, Sandell sensitivity, and detection limit are also calculated. The correlation coefficient was >/=0.9988 (n=6) with a relative standard deviation of
Michelangelo Buonocore - One of the best experts on this subject based on the ideXlab platform.
-
Reduction of Spastic Hypertonia in Patients With Spinal Cord Injury: A Double-Blind Comparison of Intravenous Orphenadrine Citrate and Placebo
Archives of physical medicine and rehabilitation, 1995Co-Authors: Roberto Casale, Chris Glynn, Michelangelo BuonocoreAbstract:Spasticity is one of the major problems affecting the outcome of rehabilitation in paraplegic patients. Orphenadrine Citrate possesses an effective muscle relaxant action in many pathologies. Nevertheless, despite a recognized central site of action, no controlled data are available on its use in the treatment of spastic hypertonia in patients with spinal cord injuries. Therefore, the effect of intravenous administration of 60mg of Orphenadrine Citrate versus placebo on spastic hypertonia after spinal cord injury was studied in 11 patients. The threshold of the flexion reflex of the lower limb was studied as a neurophysiological correlate of spastic hypertonia. Clinical assessment was made using the Ashworth Spasticity Scale. The threshold, expressed in mAmp, was studied for 60 minutes after the treatment. A significant difference was found using the active drug compared with placebo (p < 0.0001). In 9 patients, the reduction of the abnormal flexion responses after Orphenadrine appeared to begin only after 30 minutes. In one patient the onset of the therapeutic effect was early but weak. One patient with severe spastic hypertonia leading to triple flexion when the limb was manipulated did not gain any relief with Orphenadrine. The clinical and neurophysiological results suggest an efficacy of Orphenadrine Citrate in the control of spastic hypertonia in paraplegics. This could be relevant in the rehabilitation strategy, although further studies are needed on the duration of its action.
Myung Gyoon Lee - One of the best experts on this subject based on the ideXlab platform.
-
effects of cytochrome p450 inducers and inhibitors on the pharmacokinetics of intravenous furosemide in rats involvement of cyp2c11 2e1 3a1 and 3a2 in furosemide metabolism
Journal of Pharmacy and Pharmacology, 2009Co-Authors: Kyung Yang, Young Hee Choi, Unji Lee, Joo Ho Lee, Myung Gyoon LeeAbstract:Objectives It has been reported that the non-renal clearance of furosemide was significantly faster in rats pretreated with phenobarbital but was not altered in rats pretreated with 3-methylcholanthrene. However, no studies on other cytochrome P450 (CYP) isozymes have yet been reported in rats. Method Furosemide 20 mg/kg was administered intravenously to rats pretreated with various CYP inducers –3-methylcholanthrene, Orphenadrine Citrate and isoniazid, inducers of CYP1A1/2, 2B1/2 and 2E1, respectively, in rats – and inhibitors – SKF-525A (a nonspecific inhibitor of CYP isozymes), sulfaphenazole, cimetidine, quinine hydrochloride and troleandomycin, inhibitors of CYP2C6, 2C11, 2D and 3A1/2, respectively, in rats. Key findings The non-renal clearance of furosemide was significantly faster (55.9% increase) in rats pretreated with isoniazid, but slower in those pretreated with cimetidine or troleandomycin (38.5% and 22.7% decreases, respectively), than controls. After incubation of furosemide with baculovirus-infected insect cells expressing CYP2C11, 2E1, 3A1 or 3A2, furosemide was metabolized via CYP2C11, 2E1, 3A1 and 3A2. Conclusions These findings could help explain possible pharmacokinetic changes of furosemide in various rat disease models (where CYP2C11, 2E1, 3A1 and/or CYP3A2 are altered) and drug–drug interactions between furosemide and other drugs (mainly metabolized via CYP2C11, 2E1, 3A1 and/or 3A2).